Kendra L. Gully

This paper develops a mouse model of SARS-CoV-2 BA.5 infection that induces fibrotic lung disease and tertiary lymphoid structures, enabling study of acute and post-acute sequelae of COVID-19.

This paper demonstrates that MM3122, a host cell serine protease inhibitor, effectively inhibits SARS-CoV-2 replication and reduces disease severity in mice, both prophylactically and therapeutically.

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.